NCT04964934: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
- State
- Under way
- Phase
- Phase 3
- People
- 315 taking part
- Started
- 30 Jun 2021
- Primary completion
- 30 Jun 2025
- Arms
- AZD9833 + palbociclib, abemaciclib or ribociclib
- Results
- None posted
- 30 Jun 2021: Trial started
- 16 Jul 2021: Trial registered